Ranibizumab 0.5 Mg Treatment in Adolescents With Choroidal Neovascularization: Subgroup Analysis Data From the Minerva Study

Abstract

In the 12-month MINERVA study, a subgroup of 5 adolescent patients aged 13–17 years received open-label ranibizumab 0.5 mg at baseline, followed by individualized pro re nata regimen based on disease activity, for the treatment of choroidal neovascularization. Visual and anatomical outcomes were improved, and no new safety findings were observed with ranibizumab.

Unilateral macular neovascularization formation during the follow-up of a 15-year-old boy with Bietti crystalline dystrophy and the successful treatment outcome with a single intravitreal ranibizumab injection

“…MNV is a rare clinical finding in children that can cause significant visual impairment if left untreated [ 14 ], [ 15 ]. Posterior uveitis/post inflammation, retinal dystrophies, ocular trauma, neoplasms, pathological myopia and idiopathic variety are among the causes of pediatric MNVs and retinal dystrophies are present only in 11.5 [ 16 ] to 39.5% [ 17 ] of the pediatric cases.…”

“…On the other hand, fewer anti-VEGF injections seems to be required in children with MNV when compared to adult patients with wet-type age-related macular degeneration [ 18 ]. The efficacy and safety of ranibizumab 0.5 mg administration in five adolescent patients aged 13–17 years with any choroidal neovascularization etiology enrolled in the prospective 12 month long Minerva study was analyzed as a subgroup involving a total of 183 patients [ 15 ]. These patients received a mean of three injections (range 2–5) and retreatment was warranted only in the presence of disease activity.…”